ResearcherThe Christie NHS Foundation TrustNo recent work listed

Simon Gray

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8396-3328; OpenAlex author ID A5061127785. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2022: 1 paper

Papers 1

Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2022.02.014 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nicola de Liguori Carino · 1 shared paper, 2022 · strength 0.17
- Paper Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2022.02.014 ↗
Ángela Lamarca Lete · 1 shared paper, 2022 · strength 0.17
- Paper Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2022.02.014 ↗
Ganesh Radhakrishna · 1 shared paper, 2022 · strength 0.17
- Paper Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2022.02.014 ↗
Richard A Hubner · 1 shared paper, 2022 · strength 0.17
- Paper Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2022.02.014 ↗
Juan W. Valle · 1 shared paper, 2022 · strength 0.17
- Paper Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2022.02.014 ↗
Mairead Geraldine McNamara · 1 shared paper, 2022 · strength 0.17
- Paper Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2022.02.014 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.